QuantumSi

Quantum Si reported Q2 revenue of $344,000 (forecast $233,800), despite a 41.8% decline year over year. The company pushed the Proteus platform launch back six months to the second quarter of 2027 and announced layoffs of about 20%, with expected annual savings of $12 million. Management expects to be able to detect all 20 amino acids by the end of 2026 and says it has sufficient liquidity to fund operations into the fourth quarter of 2028, but it maintains a cautious revenue outlook for 2026. » More on de.investing.com

Quantum-Si is working with Cell Signaling Technology to develop and validate protein sequencing and detection of post-translational modifications (PTMs) on the single-molecule Proteus platform. CST will contribute PTM-specific immunoaffinity enrichment, mass spectrometry and bioinformatics to Proteus workflows; the partnership runs in two phases to create characterized datasets and to compare Proteus data with mass-spectrometry results. Quantum-Si aims for spatially resolved detection and quantification of proteins and PTMs for research applications, while continuing to advance its platform amid declining revenues and a recent share-price drop. » More on de.investing.com

At the annual general meeting, shareholders re-elected all ten nominated directors of Quantum-Si, confirmed PricewaterhouseCoopers as auditor and approved executive compensation in an advisory vote. The company is facing operational difficulties: the stock trades at $0.89 (down 37% year‑on‑year), cash reserves are being depleted rapidly and revenue fell 46% in the twelve months to Q1 2026. For Q1 2026 Quantum-Si reported EPS of -$0.10 and revenue of $258,000, both slightly above expectations; nevertheless the share price fell after the market opened. » More on de.investing.com